In the last trading session, 1.11 million shares of the Aclaris Therapeutics Inc (NASDAQ:ACRS) were traded, and its beta was 0.47. Most recently the company’s share price was $1.67, and it changed around -$0.03 or -1.76% from the last close, which brings the market valuation of the company to $180.22M. ACRS currently trades at a discount to its 52-week high of $5.17, offering almost -209.58% off that amount. The share price’s 52-week low was $0.95, which indicates that the current value has risen by an impressive 43.11% since then. We note from Aclaris Therapeutics Inc’s average daily trading volume that its 10-day average is 1.65 million shares, with the 3-month average coming to 915.90K.
Aclaris Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ACRS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Aclaris Therapeutics Inc is expected to report earnings per share of -0.12 for the current quarter.
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Instantly ACRS has showed a red trend with a performance of -1.76% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.7750 on recent trading dayincreased the stock’s daily price by 5.92%. The company’s shares are currently down -32.66% year-to-date, but still up 5.70% over the last five days. On the other hand, Aclaris Therapeutics Inc (NASDAQ:ACRS) is -19.32% down in the 30-day period. We can see from the shorts that 4.76 million shares have been sold at a short interest cover period of 7.08 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 76.14% from its current value. Analyst projections state that ACRS is forecast to be at a low of $3 and a high of $8.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
The year-over-year growth rate is expected to be 1.14%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 4.78M in revenue for the current quarter. 5 analysts expect Aclaris Therapeutics Inc to make 4.94M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.4M and 2.77M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 99.33%. Forecasts for the next quarter put sales growth at 78.60%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 15.24%. Aclaris Therapeutics Inc earnings are expected to increase by 64.91% in 2025, but the outlook is positive 19.51% per year for the next five years.
ACRS Dividends
Aclaris Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.65% of Aclaris Therapeutics Inc shares, and 82.47% of them are in the hands of institutional investors. The stock currently has a share float of 84.72%. Aclaris Therapeutics Inc stock is held by 129.0 institutions, with BML CAPITAL MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 18.2184% of the shares, which is about 12.99 million shares worth $14.29 million.
VANGUARD GROUP INC, with 6.5952% or 4.69 million shares worth $5.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.12 shares worth $3.53 million, making up 1.96% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 968.7 shares worth around $1.62 million, which represents about 0.90% of the total shares outstanding.
